Formal discussant W. Robert Lee, MD, of Duke University School of Medicine, Durham, North Carolina, placed himself firmly in the camp supporting hypofractionation as a new standard of care. “We now h...
There has been an ongoing debate about which type of radiation therapy is preferable in the treatment of localized prostate cancer: hypofractionation (larger fractions given over 4–5 weeks) or convent...
At the 2016 ASCO Annual Meeting, studies presented at the Plenary Session gave attendees new treatment strategies to employ back home. But in the emerging push to contain the cost of new cancer treat...
At the 2016 ASCO Annual Meeting, researchers reported encouraging results for several new drugs and treatment strategies for breast cancer. The ASCO Post brings you brief summaries of a select few. Ab...
Here are several abstracts selected from the proceedings of the 2016 ASCO Annual Meeting, focusing on clinical trials on therapeutics in different types of leukemia, multiple myeloma, follicular lymph...
Web-based applications have invaded mainstream culture and grabbed the attention of multitudes of people around the world. According to a study presented at the 2016 ASCO Annual Meeting, an app may al...
In patients with low-grade serous carcinoma, maintenance hormonal therapy reduced the risk of recurrence by 77%, compared with surveillance, in a retrospective cohort from The University of Texas MD ...
In the second-line metastatic breast cancer setting, the addition of pertuzumab (Perjeta) to trastuzumab (Herceptin)/capecitabine did not significantly improve progression-free survival, results of t...
Two studies presented at the 2016 ASCO Annual Meeting focused on the use of combination immunotherapy in the treatment of patients with advanced melanoma. Updated results from the phase III CheckMate...
Results of two pivotal breast cancer trials reported at the 2016 ASCO Annual Meeting confirmed the practice-changing findings that resulted from earlier findings. PALOMA-2 The phase III PALOMA-2 trial...
Atezolizumab (Tecentriq), an anti–programmed cell death ligand 1 (PD-L1) inhibitor, achieved durable responses as first-line treatment in cisplatin-ineligible patients with metastatic urothelial carci...
Adjuvant temozolomide, after radiotherapy, improves overall survival in patients with grade 3 anaplastic glioma without 1p/19q codeletion, according to a phase III EORTC (European Organization for Re...
Chimeric antigen receptor (CAR) T-cell therapy has been effective in adults and children with advanced acute lymphoblastic leukemia (ALL), but along with efficacy, the treatment can stimulate cytokine...
For de novo stage IV breast cancer, does resection of the primary tumor improve outcomes? Two studies presented at the 2016 ASCO Annual Meeting reached different conclusions. A prospective randomized...
In patients with HER2-positive early breast cancer, pathologic complete response rates after neoadjuvant therapy were higher with docetaxel plus carboplatin plus trastuzumab (Herceptin) plus pertuzuma...
The risk of recurrence in estrogen receptor–positive breast cancer is known to continue after 5 years, but just how much is that risk once endocrine therapy is stopped? The Early Breast Cancer Trialis...
How best to combine new immunotherapies is a burning question in oncology. A new study in the CheckMate series suggests that nivolumab (Opdivo) and ipilimumab (Yervoy) can be safely and effectively co...
1. General views. Photo © ASCO/Matt Herp 2016; 2. Amanda Redig, MD, PhD, recipient of the 2016 Women Who Conquer Cancer Young Investigator Award. Photo © ASCO/Danny Morton 2016; 3. Himisha B...
Initial encouraging news from a first-in-human trial suggests that the antibody-drug conjugate rovalpituzumab tesirine (Rova-T) may turn out to be a new option for patients with small cell lung cancer...
A novel immunotherapy agent, the first in its class, reduced disease progression by more than 50% when added to standard chemotherapy for patients with advanced gastric cancer, according to results fr...
A schedule of once-daily radiation therapy (66 Gy) was no better than a twice-daily schedule (45 Gy) for optimization of chemoradiotherapy in patients with limited-stage small cell lung cancer (SCLC),...
A strategy of matching molecular abnormalities in patients’ tumors to therapies targeted to those abnormalities is gaining ground, according to preliminary results of the phase IIb MyPathway study pre...
A pilot study revealed large differences in median retail prices for 23 cancer drugs in 7 different countries, with the highest retail prices identified in the United States and the lowest, in India a...
During the 2016 Annual Meeting, ASCO announced the creation of the Allen S. Lichter Visionary Leader Award to recognize ASCO members who have transformed the oncology field or significantly advanced t...
Oncologists in the United States may need to improve their efforts to reduce unnecessary care for younger patients with terminal cancer over the last 30 days of life, based on the findings of a stud...
The role of intraperitoneal (IP) chemotherapy in the treatment of advanced ovarian cancer has been debated for a long time. According to a new study presented at the 2016 ASCO Annual Meeting, a combin...
Sumanta K. Pal, MD, an ASCO spokesperson who moderated a press briefing at the 2016 ASCO Annual Meeting, commented that the data provide key insights into the feasibility of “liquid biopsy.” “We’re ...
So-called liquid biopsy identified cancer mutations in 85% of all advanced tumors, in the largest-ever evaluation of circulating tumor DNA (ctDNA) in the blood.1 In 49% of the cases, these biomarker...
A new biosimilar version of the monoclonal antibody trastuzumab (Herceptin) is getting close to the finish line in the race to develop biosimilars in oncology. The new antibody, MYL-1401O, demonstrat...
Study discussant Tiffany A. Traina, MD, Clinical Director of the Breast Medicine Service and Associate Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor of Medicine at Weil...
For the treatment of high-risk, HER2-negative early-stage breast cancer, anthracyclines were confirmed as beneficial in a joint analysis of the Anthracyclines in Early Breast Cancer (ABC) trials. Pres...
Study discussant Dominique Valteau-Couanet, MD, PhD, of the Gustave Roussy in France, said the study was “an important step” in research, by showing “Cy-THIO/mCEM [tandem autologous stem cell transp...
In children with high-risk neuroblastoma, tandem autologous stem cell transplant (ASCT) improved event-free survival rates in the ANBL0532 trial from the Children’s Oncology Group. The study was pres...
Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses in Spanish study findings on adding necitumumab to gemcitabine and cisplatin chemotherapy in the first-line treatment ...
1. “The Bean” or Cloud Gate with a little ASCO color. Photo © 2016 ASCO/Todd Buchanan. 2. ASCO CEO Allen S. Lichter, MD, FASCO, introducing ASCO President Julie M. Vose, MD, MBA, FASCO, during...
ASCO announced that a total of 58 practices in 39 states and the District of Columbia have joined CancerLinQ™, ASCO’s big data initiative to rapidly improve the quality of care for people with canc...
Toni K. Choueiri, MD, and Paul L. Nguyen, MD, both of the Dana-Farber Cancer Institute, discuss four key studies on high- and intermediate-risk prostate cancer, as well as localized disease (Abstracts...
Sagar Lonial, MD, of Emory University School of Medicine, and Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss newly reported findings on rituximab maintenance therapy i...
Fabrice Denis, MD, PhD, of the Institut Inter-regional de Cancérologie Jean Bernard, discusses findings from a phase III trial on an app used between visits for early detection of symptomatic relapse ...
Sagar Lonial, MD, of Emory University School of Medicine, and Paul G. Richardson, MD, of the Dana-Farber Cancer Institute, discuss the top presentations on multiple myeloma delivered at this year’s me...
Celestia S. Higano, MD, of the University of Washington, and Chris Parker, MD, of the Royal Marsden Hospital, discuss findings from this confirmatory study evaluating the accuracy of MRI and TRUS biop...
Lisa A. Carey, MD, of the University of North Carolina, and Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital and Institute of Cancer Research, discuss the efficacy of palbociclib plus fulves...
Vice President Joe Biden offered remarks on the White House’s National Cancer Moonshot Initiative on Monday, June 6, to attendees at the 2016 ASCO Annual Meeting in Chicago. Essential Elements “The ...
An adjuvant chemotherapy regimen improved overall survival in early-stage pancreatic cancer patients, in the large phase III European ESPAC-4 study reported at the 2016 ASCO Annual Meeting.1 The com...
Formal discussant of this trial Stuart A. Grossman, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, commented that the trial did not include a best stand...
The combination of short-course radiotherapy and temozolomide followed by maintenance with temozolomide significantly improved survival compared with short-course radiotherapy alone in newly diagnosed...
“There is a tremendous interest in longer aromatase inhibitor therapy. The Oxford Overview data, presented at ASCO, show the substantial risk of recurrence in years 5 to 15, despite an initial 5 year...
Five years of aromatase inhibitor as upfront therapy or after tamoxifen is the current standard of care for postmenopausal women with early hormone receptor–positive breast cancer. A new trial suggest...
Richard L. Schilsky, MD (right), Chief Medical Officer of ASCO, talks with incoming ASCO CEO Clifford A. Hudis, MD (left) and outgoing CEO Allen S. Lichter, MD (center) about the passing of the torch ...
Study discussant Paul G. Richardson, MD, the RJ Corman Professor of Medicine at Harvard Medical School and the Jerome Lipper Multiple Myeloma Chair at Dana-Farber Cancer Institute, Boston, commented,...